(Q38128460)

29 August 2017

Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches (English)

1 reference

29 August 2017

0 references

1

Ernesto Canalis

0 references

author name string

Ernesto Canalis

series ordinal

1

1 reference

29 August 2017

13 August 2013

1 reference

Nature Reviews Endocrinology

29 August 2017

1 reference

29 August 2017

9

1 reference

29 August 2017

10

1 reference

29 August 2017

575-583

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2013.154

29 August 2017

0 references

cites work

Osteoporosis prevention, diagnosis, and therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Future directions in osteoporosis therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Bisphosphonates in the treatment of osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Marrow stromal stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

The fate of circulating osteoblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Bone morphogenetic proteins, their antagonists, and the skeleton

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone morphogenetic protein signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Update on Wnt signaling in bone cell biology and bone disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Function of osteocytes in bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

31 March 2020

The amazing osteocyte

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Mechanisms of anabolic therapies for osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

The bone remodeling compartment: a circulatory function for bone lining cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Bone quality--the material and structural basis of bone strength and fragility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

The mechanism of coupling: a role for the vasculature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Mechanical signals as anabolic agents in bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Mechanotransduction and functional response of the skeleton to physical stress: the mechanisms and mechanics of bone adaptation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Matrix-embedded cells control osteoclast formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Osteocyte RANKL: new insights into the control of bone remodeling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

RANKL subcellular trafficking and regulatory mechanisms in osteocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Wnt/beta-catenin signaling in development and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Functional interaction of beta-catenin with the transcription factor LEF-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Wnt signaling and skeletal development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Interactions between Sox9 and beta-catenin control chondrocyte differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Essential role of beta-catenin in postnatal bone acquisition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Regulation of osteoblastogenesis and bone mass by Wnt10b

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

High bone density due to a mutation in LDL-receptor-related protein 5

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Regulation of bone mass by Wnt signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Canonical WNT Signaling Promotes Osteogenesis by Directly StimulatingRunx2Gene Expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

β-catenin promotes bone formation and suppresses bone resorption in postnatal growing mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

TREM2 and β-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Skeletal actions of insulin-like growth factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Nemo-like kinase inhibits osteoblastogenesis by suppressing bone morphogenetic protein and WNT canonical signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Secreted antagonists of the Wnt signalling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Wnt signaling: a win for bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

A new secreted protein that binds to Wnt proteins and inhibits their activities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Wif-1 is expressed at cartilage-mesenchyme interfaces and impedes Wnt3a-mediated inhibition of chondrogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Microarray analysis reveals expression regulation of Wnt antagonists in differentiating osteoblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Osteoblast-targeted expression of Sfrp4 in mice results in low bone mass.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Cerberus is a head-inducing secreted factor expressed in the anterior endoderm of Spemann's organizer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Head induction by simultaneous repression of Bmp and Wnt signalling in Xenopus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Effects of PTH on osteocyte function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Determinants of serum sclerostin in healthy pre- and postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Serum sclerostin levels in men with idiopathic osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Wise, a context-dependent activator and inhibitor of Wnt signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Identification of a secreted BMP antagonist, ectodin, integrating BMP, FGF, and SHH signals from the tooth enamel knot

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Function and biological roles of the Dickkopf family of Wnt modulators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

The role of Dickkopf-1 in bone development, homeostasis, and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Novel SOST gene mutation in a sclerosteosis patient and her parents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Bone mineral density in sclerosteosis; affected individuals and gene carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Targeted deletion of Sost distal enhancer increases bone formation and bone mass

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

High bone mass in mice expressing a mutant LRP5 gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

LRP4 mutations alter Wnt/beta-catenin signaling and cause limb and kidney malformations in Cenani-Lenz syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Recessively inherited forms of osteogenesis imperfecta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Mutations in WNT1 are a cause of osteogenesis imperfecta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Mutations in WNT1 cause different forms of bone fragility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Update in new anabolic therapies for osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Growth factor control of bone mass

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Linking colorectal cancer to Wnt signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

The mutation ROR2W749X, linked to human BDB, is a recessive mutation in the mouse, causing brachydactyly, mediating patterning of joints and modeling recessive Robinow syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

WNT5A regulates chondrocyte differentiation through differential use of the CaN/NFAT and IKK/NF-kappaB pathways.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.154

A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23938284

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRENDO.2013.154

1 reference

29 August 2017

1 reference

PubMed ID

23938284